The role of the chondrocyte in osteoarthritis

Arthritis and Rheumatism

Volumn 43, Issue 9, 2000, Pages 1916-1926

  Goldring, Mary B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX PROTEIN;

CARTILAGE DEGENERATION; COLLAGEN SYNTHESIS; CYTOKINE PRODUCTION; GENE EXPRESSION; GENE MUTATION; HUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CHONDROCYTES; CYTOKINES; HUMANS; OSTEOARTHRITIS;

EID: 0033712395     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I     Document Type: Review

References (106)

1. Extracellular matrix of cartilage: Collagen
2. Cartilage in health and disease
3. Proteoglycans: Many forms and many functions
4. Noncollagenous proteins: Glycoproteins and related molecules
5. Osteoarthritis and degenerative spine pathologies
6. Mechanical determinants of osteoarthrosis
7. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: Application to catabolism in situ and in vitro
8. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage
9. Aggrecan degradation in human cartilage: Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints
10. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: Analyses of synovial fluid from patients with osteoarthritis
11. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis
12. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis
13. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium
14. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis
15. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage
16. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage
17. Osteoarthritic lesions: Involvement of three different collagenases
18. Expression of membrane-type I matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage
19. Biochemical characterization of human collagenase-3
20. Selective enhancement of collagenase-mediated cleavage of resident of type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1)
21. Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan
22. Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgglmut at the 'aggrecanase' and the MMP sites: Characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan
23. Cell-mediated catabolism of aggrecan: Evidence that cleavage at the 'aggrecanase' site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain
24. Purification and cloning of aggrecanase-1: A member of the ADAMTS family of proteins
25. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family
26. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases: General features and genomic distribution of the ADAM-TS family
27. Activation of fibrillar collagen synthesis and phenotypic modulation of chondrocytes in early human osteoarthritic cartilage lesions
28. Phenotypic modulation of chondrocytes as a potential therapeutic target in osteoarthritis: A hypothesis
29. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage
30. Collagenase production by rheumatoid synovial cells: Stimulation by a human lymphocyte factor
31. A cartilage catabolic factor from synovium
32. Pig catabolin is a form of interleukin 1: Cartilage and bone resorb, fibroblasts make prostaglandin and collagenase, and thymocyte proliferation is augmented in response to one protein
33. Degradation of articular cartilage in culture: Regulatory factors
34. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
35. Cytokines in osteoarthritis: Mediators or markers of joint destruction?
36. The role of cytokines as inflammatory mediators in osteoarthritis: Lessons from animal models
37. Chondrocyte tumor necrosis factor receptors and focal loss of cartilage in osteoarthritis
38. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes: Identification as the type I receptor and analysis of binding kinetics and biologic function
39. The rationale for the current boom in anti-TNFα treatment: Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimize hazards?
40. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis
41. Gene therapy for rheumatic diseases
42. Role of tumour necrosis factor α in experimental arthritis: Separate activity of interleukin 1β in chronicity and cartilage destruction
43. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: Suppression of collagenase-1 expression
44. Post-transcriptional effect of IGF-I on IL-1β-induced type II secreted phospholipase A2 gene expression in rabbit articular chondrocytes
45. The role of nitric oxide in inflammation and immunity
46. Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression
47. The role of nitric oxide in articular cartilage damage
48. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: Influence of nitric oxide
49. Cyclooxygenase activity in chondrocytes from osteoarthritic and healthy cartilage
50. Nitric oxide in osteoarthritis
51. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis
52. IL-1β protects human chondrocytes from CD95-induced apoptosis
53. Regulation of collagen gene expression by prostaglandins and interleukin-1β in culture chondrocytes and fibroblasts
54. New targets for anti-inflammatory drugs
55. SB203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes
56. Characterization and quantitation of NF-κB nuclear translocation induced by interleukin-1 and tumor necrosis factor-α
57. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB
58. Mitogen-activated protein kinase and nuclear factor κB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: Possible role of trans-activating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK)
59. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor κB: Differential regulation of collagenase 1 and collagenase 3
60. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: Regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels
61. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
62. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses
63. Interleukin-1β-converting enzyme/caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of interleukin-1β and interleukin-18
64. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies
65. Effects of exogenous IL-1β, TNFα, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes
66. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint
67. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity
68. Effects of IL-6 and its soluble receptor on proteoglycan synthesis and NO release by human articular chondrocytes: Comparison with IL-1. Modulation by dexamethasone
69. 2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: Distinct targeting in the signaling pathways
70. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction
71. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model
72. Lessons for joint destruction from animal models
73. Resistance to fever induction and impaired acute-phase response in interleukin-1β-deficient mice
74. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock
75. Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice
76. DBA/1mice expressing the human TNF-α transgene develop a severe, erosive arthritis: Characterization of the cytokine cascade and cellular composition
77. Interleukin-6 reduces cartilage destruction during experimental arthritis: A study in interleukin-6-deficient mice
78. Effect of interleukin 1 and leukaemia inhibitory factor on chondrocyte metabolism in articular cartilage from normal and interleukin-6-deficient mice: Role of nitric oxide and IL-6 in the suppression of proteoglycan synthesis
79. Role of morphogenetic proteins in skeletal tissue engineering and regeneration
80. The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis
81. Growth factor actions on articular cartilage
82. The role and content of endogenous insulin-like growth factor-binding proteins in bovine articular cartilage
83. Upregulation of insulin-like growth factor I gene expression in the lesions of osteoarthritic human articular cartilage
84. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation: Possible role of IGF-1-binding proteins
85. Production of binding proteins and role of the insulin-like growth factor I binding protein 3 in human articular cartilage explants
86. Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins
87. Local disruption of the insulin-like growth factor system in the arthritic joint
88. Recombinant human bone morphogenetic protein-2 maintains the articular chondrocyte phenotype in long-term culture
89. Different effects of bone morphogenetic proteins 2, 4, 12, and 13 on the expression of cartilage and bone markers in the MC615 chondrocyte cell line
90. Phenotypic stability of articular chondrocytes in vitro: The effects of culture models, bone morphogenetic protein 2, and serum supplementation
91. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: In vitro mimicking effect by transforming growth factor β
92. Chondrocyte cytokine and growth factor expression in murine osteoarthritis
93. Osteoarthritis-like changes in the murine knee joint resulting from intra-articular transforming growth factor-β injections
94. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage
95. Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in vivo but does not counteract interleukin-1α effects on proteoglycan synthesis and content
96. Treatment of canine osteoarthritis with insulin-like growth factor-1 (IGF-1) and sodium pentosan polysulfate
97. Heritable diseases of the skeleton. Part I. Molecular insights into skeletal development-transcription factors and signaling pathways
98. Heritable diseases of the skeleton. Part II. Molecular insights into skeletal development-matrix components and their homeostasis
99. Genetics and osteoarthritis: Exposing the iceberg
100. Transgenic mice with deficiencies in cartilage collagens: Possible models for gene therapy
101. The ins and outs of aggrecan
102. An association between an aggrecan polymorphic allele and bilateral hand osteoarthritis in elderly white men: Data from the Baltimore Longitudinal Study of Aging (BLSA)
103. Skeletal and hematopoietic defects in mice transgenic for collagen X
104. Articular cartilage repair and transplantation
105. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation
106. Principles of cartilage repair and regeneration